A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors
Latest Information Update: 05 Nov 2018
At a glance
- Drugs AMG 337 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Amgen
- 26 Oct 2018 Results published in the Clinical Cancer Research
- 22 Mar 2017 This trial was completed in United Kingdom (end date: 2016-10-10), according to European Clinical Trials Database.
- 11 Feb 2017 This trial was completed in Poland, according to European Clinical Trials Database